ATE540689T1 - Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon - Google Patents

Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon

Info

Publication number: ATE540689T1
Authority: AT; Austria
Prior art keywords: treat; disorders; ribose; parp; poly
Prior art date: 2005-11-14

Application number

AT06820897T

Other languages

English (en)

Inventor

Ali Hamiche

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-14

Filing date

2006-11-14

Publication date

2012-01-15

2006-11-14 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE540689T1 publication Critical patent/ATE540689T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 2
108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 title 1
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title 1
-1 poly(adenosine 5′-diphospho-ribose) Polymers 0.000 abstract 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000002193 Pain Diseases 0.000 abstract 2
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
206010040070 Septic Shock Diseases 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
208000015122 neurodegenerative disease Diseases 0.000 abstract 2
230000009758 senescence Effects 0.000 abstract 2
230000000451 tissue damage Effects 0.000 abstract 2
231100000827 tissue damage Toxicity 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
206010014824 Endotoxic shock Diseases 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
102000003960 Ligases Human genes 0.000 abstract 1
108090000364 Ligases Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000012661 PARP inhibitor Substances 0.000 abstract 1
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
108091026813 Poly(ADPribose) Proteins 0.000 abstract 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
208000005298 acute pain Diseases 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000005779 cell damage Effects 0.000 abstract 1
230000030833 cell death Effects 0.000 abstract 1
208000037887 cell injury Diseases 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
206010009887 colitis Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
230000001146 hypoxic effect Effects 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
230000017074 necrotic cell death Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
208000004296 neuralgia Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000021722 neuropathic pain Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000008943 replicative senescence Effects 0.000 abstract 1
208000032253 retinal ischemia Diseases 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
210000002027 skeletal muscle Anatomy 0.000 abstract 1
230000009759 skin aging Effects 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Immunology (AREA)
Hematology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Biomedical Technology (AREA)

AT06820897T 2005-11-14 2006-11-14 Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon ATE540689T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73658805P	2005-11-14	2005-11-14
PCT/IB2006/003224 WO2007054814A1 (en)	2005-11-14	2006-11-14	Inhibitors of parp activity and uses thereof

Publications (1)

Publication Number	Publication Date
ATE540689T1 true ATE540689T1 (de)	2012-01-15

Family

ID=37836670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06820897T ATE540689T1 (de)	2005-11-14	2006-11-14	Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon

Country Status (7)

Country	Link
US (1)	US9150628B2 (de)
EP (1)	EP1948215B1 (de)
JP (1)	JP5221368B2 (de)
AT (1)	ATE540689T1 (de)
CA (1)	CA2629376C (de)
ES (1)	ES2380803T3 (de)
WO (1)	WO2007054814A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2270510A1 (de) *	2009-07-02	2011-01-05	EMBL (European Molecular Biology Laboratory)	Diagnoseverfahren zur Vorhersage des Krebsrekurrenzrisikos basierend auf Histon-macroH2A-Isoformen
CN108601793B (zh)	2016-02-18	2024-08-23	伊维萨股份有限公司	使用5′-腺苷二磷酸核糖(adpr)的方法
US11413288B2 (en)	2017-11-01	2022-08-16	Dana-Farber Cancer Institute, Inc.	Methods of treating cancers
WO2019191026A2 (en)	2018-03-27	2019-10-03	Invirsa, Inc.	Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN119736252B (zh) *	2025-01-15	2025-06-27	首都医科大学	组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5215738A (en)	1985-05-03	1993-06-01	Sri International	Benzamide and nicotinamide radiosensitizers
US5032617A (en)	1985-05-03	1991-07-16	Sri International	Substituted benzamide radiosensitizers
US5041653A (en)	1985-05-03	1991-08-20	Sri International	Substituted benzamide radiosensitizers
US5177075A (en)	1988-08-19	1993-01-05	Warner-Lambert Company	Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5997856A (en)	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JP3140757B2 (ja)	1989-02-06	2001-03-05	デイナ・フアーバー・キヤンサー・インステイテユート	パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
GB9404485D0 (en)	1994-03-09	1994-04-20	Cancer Res Campaign Tech	Benzamide analogues
US5589483A (en)	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
CA2225465A1 (en)	1995-08-02	1997-02-13	Newcastle University Ventures Limited	Benzimidazole compounds
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
GB9702701D0 (en)	1997-02-01	1997-04-02	Univ Newcastle Ventures Ltd	Quinazolinone compounds
US5981221A (en) *	1997-03-26	1999-11-09	Incyte Pharmaceuticals, Inc.	Histone fusion protein
CA2288306A1 (en)	1997-04-28	1998-11-05	Rhone-Poulenc Rorer S.A.	Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20020022636A1 (en)	1997-09-03	2002-02-21	Jia-He Li	Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en)	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en)	1997-09-03	2001-03-06	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298098A (en)	1997-09-03	1999-03-22	Guilford Pharmaceuticals Inc.	Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en)	1997-09-03	1999-03-11	Guilford Pharmaceuticals Inc.	Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en)	1997-09-03	2002-03-07	Paul F. Jackson	Thioalkyl compounds, methods, and compositions for inhibiting parp activity
DE69941703D1 (de)	1999-10-11	2010-01-07	Pasteur Institut	Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
FR2805821B1 (fr)	2000-03-01	2004-01-16	Diatos	Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
CA2417454A1 (en)	2000-07-31	2002-02-07	Active Motif	Peptide-mediated delivery of molecules into cells
US6859652B2 (en) *	2000-08-02	2005-02-22	Mobile Satellite Ventures, Lp	Integrated or autonomous system and method of satellite-terrestrial frequency reuse using signal attenuation and/or blockage, dynamic assignment of frequencies and/or hysteresis
FR2849603B1 (fr)	2003-01-07	2006-09-08	Centre Nat Rech Scient	Composition pour le transport intracellulaire de macromolecules ou particules biologiques
JP2005052101A (ja)	2003-08-06	2005-03-03	Zoegene Corp	新規タンパク質およびそれをコードするｄｎａ
EP1512696A1 (de)	2003-08-14	2005-03-09	Diatos	Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern
EP1732596A2 (de) *	2004-03-11	2006-12-20	Shantha West, Inc.	Therapeutische verwendung des rm1-antigens
WO2006119435A2 (en) *	2005-05-04	2006-11-09	Invitrogen Corporation	Identification of cancer biomarkers and phosphorylated proteins
US7842467B1 (en) *	2005-05-12	2010-11-30	Celera Corporation	Breast disease targets and uses thereof

2006
- 2006-11-14 CA CA2629376A patent/CA2629376C/en not_active Expired - Fee Related
- 2006-11-14 EP EP06820897A patent/EP1948215B1/de not_active Not-in-force
- 2006-11-14 JP JP2008539534A patent/JP5221368B2/ja not_active Expired - Fee Related
- 2006-11-14 ES ES06820897T patent/ES2380803T3/es active Active
- 2006-11-14 AT AT06820897T patent/ATE540689T1/de active
- 2006-11-14 US US12/084,873 patent/US9150628B2/en not_active Expired - Fee Related
- 2006-11-14 WO PCT/IB2006/003224 patent/WO2007054814A1/en not_active Ceased

Also Published As

Publication number	Publication date
US20100323974A1 (en)	2010-12-23
ES2380803T3 (es)	2012-05-18
CA2629376C (en)	2015-06-09
WO2007054814A1 (en)	2007-05-18
EP1948215A1 (de)	2008-07-30
JP5221368B2 (ja)	2013-06-26
JP2009519216A (ja)	2009-05-14
EP1948215B1 (de)	2012-01-11
US9150628B2 (en)	2015-10-06
CA2629376A1 (en)	2007-05-18

Publication	Publication Date	Title
WO2009151598A8 (en)	2010-05-06	Diazacarbazoles and methods of use
WO2007030697A3 (en)	2007-05-03	Modulation of neurogenesis by hdac inhibition
WO2014194245A3 (en)	2015-01-29	Cdk8 inhibitors and uses thereof
MY159449A (en)	2017-01-13	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
MX2010005300A (es)	2010-06-25	4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
EA201100749A1 (ru)	2011-10-31	Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
MY178660A (en)	2020-10-20	Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
MX2012013081A (es)	2013-05-09	Compuestos utiles como inhibidores de cinasa atr.
MX2011006503A (es)	2011-09-06	Derivados de pirazina utiles como inhibidores de la cinasa de atr.
PH12012500778A1 (en)	2012-11-26	IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EA201301353A1 (ru)	2014-05-30	Композиции и способы получения пиримидиновых и пиридиновых соединений с втк ингибирующей активностью
WO2011143425A3 (en)	2012-02-23	Compounds useful as inhibitors of atr kinase
WO2010005876A3 (en)	2010-07-01	Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008121687A3 (en)	2008-11-20	Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2010068483A3 (en)	2010-09-30	Mlk inhibitors and methods of use
WO2010147898A3 (en)	2011-05-12	Small molecule inhibitors of spleen tyrosine kinase (syk)
NZ503043A (en)	2002-10-25	Poly(ADP-ribose) polymerase (PARP) inhibitors for treating neural or cardiovascular tissue damage
EA201290894A1 (ru)	2013-04-30	Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
MX2011012353A (es)	2011-12-14	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
EA020703B9 (ru)	2015-12-30	Пиразолохиназолины
PH12012501749A1 (en)	2015-02-25	Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
MX349550B (es)	2017-08-02	1,7-diazacarbazoles y metodos de uso.
MX2007003360A (es)	2007-05-23	Derivados de 5-arilamino-ah-piridin-2-ona 3,6-sustituidos y compuestos relacionados como inhibidores de la poli (adp-ribosa)-polimerasa (parp) en el tratamiento de dano de tejidos o enfermedades producidas por necrosis o apoptosis.
WO2006124354A3 (en)	2007-11-15	Tyrosine kinase inhibitors
WO2012048259A3 (en)	2012-06-28	Substituted pyridazine carboxamide compounds